These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

487 related items for PubMed ID: 17391170

  • 1. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
    Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Lüddeke HJ.
    Diabetes Obes Metab; 2007 May; 9(3):418-27. PubMed ID: 17391170
    [Abstract] [Full Text] [Related]

  • 2. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K.
    Cochrane Database Syst Rev; 2020 Nov 09; 11(11):CD005613. PubMed ID: 33166419
    [Abstract] [Full Text] [Related]

  • 3. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
    Dornhorst A, Lüddeke HJ, Koenen C, Meriläinen M, King A, Robinson A, Sreenan S, PREDICTIVE Study Group.
    Diabetes Obes Metab; 2008 Jan 09; 10(1):75-81. PubMed ID: 18034846
    [Abstract] [Full Text] [Related]

  • 4. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.
    Clin Ther; 2008 Nov 09; 30(11):1976-87. PubMed ID: 19108786
    [Abstract] [Full Text] [Related]

  • 5. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes.
    Valentine WJ, Goodall G, Aagren M, Nielsen S, Palmer AJ, Erny-Albrecht K.
    Adv Ther; 2008 Jun 09; 25(6):567-84. PubMed ID: 18568451
    [Abstract] [Full Text] [Related]

  • 6. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes.
    Fakhoury W, Lockhart I, Kotchie RW, Aagren M, LeReun C.
    Pharmacology; 2008 Jun 09; 82(2):156-63. PubMed ID: 18679040
    [Abstract] [Full Text] [Related]

  • 7. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia.
    Davies MJ, Derezinski T, Pedersen CB, Clauson P.
    Diabetes Technol Ther; 2008 Aug 09; 10(4):273-7. PubMed ID: 18715200
    [Abstract] [Full Text] [Related]

  • 8. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.
    Health Technol Assess; 2010 Jul 09; 14(36):1-248. PubMed ID: 20646668
    [Abstract] [Full Text] [Related]

  • 9. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
    Janka HU, Plewe G, Busch K.
    J Am Geriatr Soc; 2007 Feb 09; 55(2):182-8. PubMed ID: 17302653
    [Abstract] [Full Text] [Related]

  • 10. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study.
    Dornhorst A, Lüddeke HJ, Sreenan S, Kozlovski P, Hansen JB, Looij BJ, Meneghini L, PREDICTIVE Study Group.
    Int J Clin Pract; 2008 Apr 09; 62(4):659-65. PubMed ID: 18324957
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study.
    Dornhorst A, Lüddeke HJ, Honka M, Ackermann RW, Meriläinen M, Gallwitz B, Sreenan S, PREDICTIVE Study Group.
    Curr Med Res Opin; 2008 Feb 09; 24(2):369-76. PubMed ID: 18096110
    [Abstract] [Full Text] [Related]

  • 12. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
    Johansen OE, Vanberg PJ, Kilhovd BK, Jørgensen AP.
    Vasc Health Risk Manag; 2009 Feb 09; 5(1):121-8. PubMed ID: 19436668
    [Abstract] [Full Text] [Related]

  • 13. Comparative effectiveness and safety of different basal insulins in a real-world setting.
    Ji L, Zhang P, Zhu D, Lu J, Guo X, Wu Y, Li X, Ji J, Jia W, Yang W, Zou D, Zhou Z, Gao Y, Garg SK, Pan C, Weng J, Paul SK, ORBIT study group.
    Diabetes Obes Metab; 2017 Aug 09; 19(8):1116-1126. PubMed ID: 28230322
    [Abstract] [Full Text] [Related]

  • 14. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.
    Clin Ther; 2004 May 09; 26(5):724-36. PubMed ID: 15220016
    [Abstract] [Full Text] [Related]

  • 15. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
    Yki-Järvinen H, Dressler A, Ziemen M, HOE 901/300s Study Group.
    Diabetes Care; 2000 Aug 09; 23(8):1130-6. PubMed ID: 10937510
    [Abstract] [Full Text] [Related]

  • 16. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B, Metzendorf MI, Richter B.
    Cochrane Database Syst Rev; 2021 Mar 04; 3(3):CD013498. PubMed ID: 33662147
    [Abstract] [Full Text] [Related]

  • 17. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study.
    Meneghini LF, Dornhorst A, Sreenan S, PREDICTIVE Study Group.
    Curr Med Res Opin; 2009 Apr 04; 25(4):1029-35. PubMed ID: 19281426
    [Abstract] [Full Text] [Related]

  • 18. PREDICTIVE- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort.
    Lüddeke HJ, Sreenan S, Aczel S, Maxeiner S, Yenigun M, Kozlovski P, Gydesen H, Dornhorst A, PREDICTIVE Study Group.
    Diabetes Obes Metab; 2007 May 04; 9(3):428-34. PubMed ID: 17391171
    [Abstract] [Full Text] [Related]

  • 19. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.
    Standl E, Lang H, Roberts A.
    Diabetes Technol Ther; 2004 Oct 04; 6(5):579-88. PubMed ID: 15628811
    [Abstract] [Full Text] [Related]

  • 20. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study.
    Kurtoglu S, Atabek ME, Dizdarer C, Pirgon O, Isguven P, Emek S, PREDICTIVE Turkey Study Group.
    Pediatr Diabetes; 2009 Sep 04; 10(6):401-7. PubMed ID: 19220776
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.